CFGI Promotes New Partners for 2021
We are excited to announce our newly promoted CFGI Partners.
Vor Biopharma Closes Over $203.4 Million Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Capital Markets team assisted Vor Biopharma (NASDAQ: VOR) with their initial public offering.
Ortho Clinical Diagnostics Holdings PLC Closes $1.49 Billion Initial Public Offering of Ordinary Shares Trading on the NASDAQ Global Select Market
CFGI’s Capital Markets team assisted Ortho Clinical Diagnostics Holdings PLC (NASDAQ: OCDX) with their initial public offering.
Clene Nanomedicine Inc. Closes Business Combination with SPAC Tottenham Acquisition I Limited
CFGI’s Capital Markets team assisted Clene Nanomedicine (“Clene”) (NYSE: CLNN) with its SPAC merger with Tottenham Acquisition I Limited (“Tottenham”).
Meet Robert Keep: CFGI’s Boston Office Leader and Accounting Advisory Expert
CFGI’s Robert Keep may be English by birth, but he’s a Bostonian through and through.
Olema Pharmaceuticals Closes $209 Million Initial Public Offering with Support from CFGI
CFGI’s Capital Markets team supported Olema Pharmaceuticals (Nasdaq: OLMA) with an initial public offering of 11,000,000 shares of common stock priced at $19.